Durability of recaptured response to ozanimod during the True North open-label extension

被引：0
|
作者：
Dignass, A. [1 ]
Regueiro, M. [2 ]
Colombel, J. F. [3 ]
Jain, A. [4 ]
Canavan, J. B. [4 ]
Wu, H. [4 ]
Lawlor, G. [4 ]
Osterman, M. T. [4 ]
Vermeire, S. [5 ]
Rubin, D. T. [6 ]
机构：
[1] Goethe Univ, Med, Agaples Markus Hosp, Frankfurt, Germany
[2] Cleveland Clin Cleveland, Digest Dis & Surg Inst, Cleveland, OH USA
[3] Icahn Sch Med Mt Sinai, Gastroenterol, New York, NY USA
[4] Bristol Myers Squibb, Clin Res, Princeton, NJ USA
[5] Univ Leuven, Chron Dis & Metab, Leuven, Belgium
[6] Univ Chicago, Gastroenterol, Chicago, IL USA
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P687
引用
收藏
页码：817 / 818
页数：2
相关论文
共 50 条
  • [21] Endoscopic, histologic, and combined outcomes with reinitiation of ozanimod after temporary discontinuation: 2-year interim analysis of the True North open-label extension study
    Vermeire, S.
    Dignass, A.
    Colombel, J. F.
    Jain, A.
    Canavan, J. B.
    Wu, H.
    Lawlor, G.
    Osterman, M. T.
    Rubin, D. T.
    Regueiro, M.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I103 - I104
  • [22] ENDOSCOPIC, HISTOLOGIC, AND COMBINED OUTCOMES WITH REINITIATION OF OZANIMOD AFTER TEMPORARY DISCONTINUATION: 2-YEAR INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
    Regueiro, Miguel D.
    Dignass, Axel
    Colombel, Jean Frederic
    Jain, Anjali
    Canavan, James B.
    Wu, Hsiuanlin
    Lawlor, Garrett
    Osterman, Mark T.
    Rubin, David T.
    Vermeire, Severine
    GASTROENTEROLOGY, 2023, 164 (06) : S1105 - S1105
  • [23] Safety patterns with ozanimod during phase 3 and open-label extension trials in patients with relapsing multiple sclerosis
    Selmaj, K. W.
    Ziemssen, T.
    Comi, G.
    Hartung, H. -P.
    Singal, M.
    Riolo, J. V.
    Cheng, C. -Y.
    Sheffield, J. K.
    Minton, N.
    Vermersch, P.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 641 - 642
  • [24] Hepatic safety of ozanimod in relapsing multiple sclerosis in the DAYBREAK open-label extension study
    Selmaj, K.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Minton, N.
    Afsari, S.
    Shi, F.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 608 - 609
  • [25] Sustained Efficacy and Safety After 5 Years of Continuous Ozanimod Treatment Independent of Clinical Remission Status: An Interim Analysis of the True North Open-Label Extension Study
    Cross, Raymond K.
    Danese, Silvio
    Wolf, Douglas C.
    Matsuoka, Katsuyoshi
    Dotan, Iris
    Boland, Brigid S.
    Raffals, Laura E.
    Mehra, Dimpy
    Santiago, Norma Ruiz
    Petersen, AnnKatrin
    Desai, Manik
    Wu, Hsiuanlin
    Wang, Dong
    Osterman, Mark T.
    Jain, Anjali
    Lindsay, James O.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10): : S853 - S854
  • [26] Sustained Efficacy and Safety After 5 Years of Continuous Ozanimod Treatment Independent of Clinical Remission Status: An Interim Analysis of the True North Open-Label Extension Study
    Cross, Raymond K.
    Danese, Silvio
    Wolf, Douglas C.
    Matsuoka, Katsuyoshi
    Dotan, Iris
    Boland, Brigid S.
    Raffals, Laura E.
    Mehra, Dimpy
    Santiago, Norma Ruiz
    Petersen, Annkatrin
    Desai, Manik
    Wu, Hsiuanlin
    Wang, Dong
    Osterman, Mark T.
    Jain, Anjali
    Lindsay, James O.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S853 - S854
  • [27] Absolute Lymphocyte Count Around Infections During Phase 3 and Open-Label Extension Trials of Ozanimod in Participants With Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study
    Hartung, Hans-Peter
    Steinman, Lawrence
    Bar-Or, Amit
    Sheffield, James
    Cheng, Chun-Yen
    Riolo, Jon
    Harris, Sarah
    Reardon, Jennifer
    Thorpe, Andrew
    Cree, Bruce A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1016 - 1017
  • [28] Update on Hepatic Safety of Ozanimod in Relapsing Multiple Sclerosis in the DAYBREAK Open-Label Extension Trial
    Selmaj, K. W.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Hartung, H. P.
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Thorpe, A.
    Riolo, J. V.
    Krakovich, A.
    Cheng, C. Y.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 325 - 326
  • [29] Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study (vol 18, p i1823, 2024)
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (08): : 1357 - 1357
  • [30] Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extension
    Siegel, C.
    Danese, S.
    Rubin, D. T.
    Sabino, J.
    Long, M. D.
    Cross, R. K.
    Armuzzi, A.
    Blumenstein, I.
    Kobayashi, T.
    Lama, S.
    Charles, L.
    Cetin, V.
    Petersen, A.
    Wu, H.
    Wang, D.
    Jain, A.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I100 - I101
12345